SynthesisPediatric research2025
Beneficial vs harmful effects of pharmacological treatment of patent ductus arteriosus: A Bayesian meta-analysis.
Synthesis in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Two-Year Outcomes of a Randomized Controlled Trial of Nonintervention Versus Oral Ibuprofen for Patent Ductus Arteriosus in Premature Infants.Journal of Korean medical science · 2026Trial
- A Pathophysiological Approach for Early Detection and Prevention of AKI in the NICU.American journal of perinatology · 2026Review
- EBNEO Commentary: Expectant Management Versus Medication for Patent Ductus Arteriosus in Preterm Infants-The PDA RCT.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- Making sense of the evidence: designing randomised controlled trials for preterm infants with high-shunt volume patent ductus arteriosus.Archives of disease in childhood. Fetal and neonatal edition · 2026Review
- The association between patent ductus arteriosus and adverse outcomes in preterm infants.BMC pediatrics · 2026Article
- PDA in Prematurity: Rethinking a Decades-Old Debate in 2026.Biomedicines · 2026Review
- Pharmacologic treatment strategies and association with major neonatal outcomes for patent ductus arteriosus in preterm infants.Frontiers in pediatrics · 2026Article
- Impact of patent ductus arteriosus treatment on neonatal outcomes in preterm infants with or without perinatal acidosis: a nationwide cohort study.BMC pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized controlled trials (RCTs) have failed to demonstrate the beneficial effects of the pharmacological treatment of patent ductus arteriosus (PDA) in preterm infants. We conducted a Bayesian model averaged (BMA) meta-analysis of RCTs comparing the pharmacological treatment of PDA with placebo or expectant treatment.
methodsWe searched for RCTs including infants with gestational age (GA) ≤ 32 weeks and with a rate of open-label treatment of less than 25% in the control arm. The primary outcome was mortality and secondary outcomes included bronchopulmonary dysplasia (BPD). We calculated Bayes factors (BFs). The BF
resultsFive RCTs were included (1341 infants). BMA showed strong evidence in favor of the harmful effect of medication for BPD (BF
conclusionPharmacological treatment of PDA in extremely preterm infants may result in more complications than clinical benefit. IMPACT: Randomized controlled trials spanning several decades have investigated the pharmacological treatment of patent ductus arteriosus (PDA) but have failed to demonstrate an improvement in mortality or short-term morbidity. We conducted a Bayesian meta-analysis to answer the question: Is the pharmacological treatment of PDA beneficial or harmful in very and extremely preterm infants? Bayesian meta-analysis showed strong evidence in favor of higher rates of bronchopulmonary dysplasia (BPD) and death or BPD in infants receiving pharmacological treatment of PDA when compared with infants receiving placebo or expectant management. Pharmacological treatment of PDA in extremely preterm infants may result in more complications than clinical benefit.
Indexed as
Identifiers
39815089What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.